Akebia Therapeutics Inc (AKBA)

Currency in USD
0.3855
-0.0368(-8.71%)
Closed·
0.3990+0.0135(+3.50%)
·
AKBA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.38490.4331
52 wk Range
0.36121.7300
Key Statistics
Prev. Close
0.3855
Open
0.41
Day's Range
0.3849-0.4331
52 wk Range
0.3612-1.73
Volume
4.57M
Average Volume (3m)
8.03M
1-Year Change
-75.129%
Book Value / Share
0.074
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AKBA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.6667
Upside
+591.74%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Akebia Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.6667
(+591.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy2.00+418.81%4.00MaintainNov 16, 2026
H.C. Wainwright
Buy4.00+937.61%6.00MaintainNov 06, 2026
WestPark Capital
Buy4.50+1,067.32%-New CoverageSep 08, 2026
Leerink
Hold1.00+159.40%-DowngradeAug 07, 2026
H.C. Wainwright
Buy6.00+1,456.42%-MaintainAug 06, 2026

Akebia Therapeutics Inc Earnings Call Summary for Q2/2026

  • Akebia posted Q2 2026 adjusted loss of $0.03/share, beating estimates by $0.01, but revenue fell 21.5% YoY to $49M, missing forecasts by $1.93M.
  • Vafseo sales surged 60% YoY to $21.3M with 10,500+ active patients, while Auryxia plunged 46% to $25.5M amid generic competition and pricing pressure.
  • Shares dropped 24% after-hours to $0.98 as management warned 2027 revenue could decline when Vafseo's TDAPA premium pricing ends December 31, 2026.
  • VOICE trial met primary endpoint, strengthening Vafseo's clinical profile; Phase II trials progressing for ebribafusp and praliciguat in rare kidney diseases.
  • Company holds $155.5M cash, expects two-year runway with planned debt refinancing; DaVita adoption remains gradual despite operational progress discussions.
Last Updated: 2026-08-05, 05:26 p/m
Read Full Transcript

Earnings

Latest Release
Nov 05, 2026
EPS / Forecast
-0.05 / -0.04
Revenue / Forecast
36.9M / 46.55M
EPS Revisions
Last 90 days

AKBA Income Statement

Compare AKBA to Peers and Sector

Metrics to compare
AKBA
Peers
Sector
Relationship
P/E Ratio
−2.4x−1.0x−0.2x
PEG Ratio
0.02−0.020.00
Price/Book
5.3x1.7x2.6x
Price / LTM Sales
0.5x2.2x2.6x
Upside (Analyst Target)
-172.6%76.9%
Fair Value Upside
Unlock18.6%14.9%Unlock

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Employees
194

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
49.50M17.83%20.24M
Other Institutional Investors
67.25M24.22%27.50M
Public Companies & Retail Investors
160.91M57.95%65.80M
Total
277.66M100.00%113.54M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.20%19,986,3748,172
Vanguard Capital Management, LLC4.77%13,230,9405,410

People Also Watch

3.820
ATYR
+3.52%
5.270
CRMD
+3.74%
0.2500
PLCEQ
-28.59%
0.0027
SHFS
+3.85%
0.2342
EYPT
-11.36%

FAQ

What Is the Akebia (AKBA) Stock Price Today?

The Akebia stock price today is 0.3855 USD.

What Stock Exchange Does Akebia Trade On?

Akebia is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Akebia?

The stock symbol for Akebia is "AKBA."

What Is the Akebia Market Cap?

As of today, Akebia market cap is 117.2600M USD.

What Is Akebia's Earnings Per Share (TTM)?

The Akebia EPS (TTM) is -0.17.

When Is the Next Akebia Earnings Date?

Akebia will release its next earnings report on Mar 03, 2027.

From a Technical Analysis Perspective, Is AKBA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Akebia Stock Split?

Akebia has split 0 times.

How Many Employees Does Akebia Have?

Akebia has 194 employees.

What is the current trading status of Akebia (AKBA)?

As of Nov 21, 2026, Akebia (AKBA) is trading at a price of 0.3855 USD, with a previous close of 0.3855 USD. The stock has fluctuated within a day range of 0.3849 USD to 0.4331 USD, while its 52-week range spans from 0.3612 USD to 1.7300 USD.

What Is Akebia (AKBA) Price Target According to Analysts?

The average 12-month price target for Akebia is 2.6667 USD, with a high estimate of 4 USD and a low estimate of 1 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +591.74% Upside potential.

What Is the AKBA Premarket Price?

AKBA's last pre-market stock price is 0.4100 USD. The pre-market share volume is 12,370.0000, and the stock has decreased by -0.0123, or -2.9100%.

What Is the AKBA After Hours Price?

AKBA's last after hours stock price is 0.3990 USD, the stock has decreased by 0.0135, or 3.5000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.